Lyka Labs Limited (LYKALABS.NS)
INR 110.46
(2.73%)
INR 110.46
(2.73%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 29.13 Million INR | -49.68% |
| 2022 | 57.89 Million INR | -93.2% |
| 2021 | 851.66 Million INR | 574.98% |
| 2020 | 126.17 Million INR | 191.24% |
| 2019 | -138.28 Million INR | -54.4% |
| 2018 | -89.56 Million INR | 41.32% |
| 2017 | -152.62 Million INR | -305.25% |
| 2016 | 74.35 Million INR | -10.79% |
| 2015 | 83.34 Million INR | -50.11% |
| 2014 | 167.07 Million INR | 248.54% |
| 2013 | -112.47 Million INR | -1893.69% |
| 2012 | 6.27 Million INR | 0.0% |
| 2011 | - INR | -100.0% |
| 2010 | 227.08 Million INR | 37.65% |
| 2009 | 164.97 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 19.5 Million INR | 324.08% |
| 2023 Q2 | 8.29 Million INR | 285.57% |
| 2023 FY | 29.13 Million INR | -49.68% |
| 2023 Q3 | 45.64 Million INR | 450.17% |
| 2023 Q1 | -4.47 Million INR | -880.48% |
| 2023 Q4 | -8.7 Million INR | -119.07% |
| 2022 Q3 | -1.95 Million INR | -107.54% |
| 2022 Q2 | 25.97 Million INR | -24.36% |
| 2022 Q1 | 34.33 Million INR | 16.41% |
| 2022 FY | 57.89 Million INR | -93.2% |
| 2022 Q4 | -456 Thousand INR | 76.7% |
| 2021 Q3 | 111.81 Million INR | -73.87% |
| 2021 Q2 | 427.98 Million INR | 51.57% |
| 2021 Q1 | 282.37 Million INR | 531.26% |
| 2021 FY | 851.66 Million INR | 574.98% |
| 2021 Q4 | 29.49 Million INR | -73.62% |
| 2020 Q2 | 17.17 Million INR | -23.49% |
| 2020 FY | 126.17 Million INR | 191.24% |
| 2020 Q3 | 41.83 Million INR | 143.65% |
| 2020 Q4 | 44.73 Million INR | 6.92% |
| 2020 Q1 | 22.44 Million INR | 138.67% |
| 2019 Q4 | -58.03 Million INR | -93.05% |
| 2019 Q1 | -27.3 Million INR | 8.88% |
| 2019 FY | -138.28 Million INR | -54.4% |
| 2019 Q2 | -22.88 Million INR | 16.16% |
| 2019 Q3 | -30.06 Million INR | -31.35% |
| 2018 Q2 | -64.1 Million INR | 9.95% |
| 2018 Q4 | -29.96 Million INR | -212.61% |
| 2018 FY | -89.56 Million INR | 41.32% |
| 2018 Q1 | -71.18 Million INR | 0.0% |
| 2018 Q3 | 26.6 Million INR | 141.5% |
| 2017 FY | -152.62 Million INR | -305.25% |
| 2016 Q1 | 1.03 Million INR | -98.32% |
| 2016 FY | 74.35 Million INR | -10.79% |
| 2016 Q4 | 56.52 Million INR | 43.98% |
| 2016 Q3 | 39.25 Million INR | -26.39% |
| 2016 Q2 | 53.33 Million INR | 5033.01% |
| 2015 Q2 | 43.19 Million INR | -46.2% |
| 2015 Q4 | 61.98 Million INR | 496.15% |
| 2015 Q3 | 10.39 Million INR | -75.93% |
| 2015 Q1 | 80.29 Million INR | 134.0% |
| 2015 FY | 83.34 Million INR | -50.11% |
| 2014 Q2 | 38.72 Million INR | 1736.52% |
| 2014 Q1 | -2.36 Million INR | 0.0% |
| 2014 Q4 | 34.31 Million INR | -74.95% |
| 2014 Q3 | 136.99 Million INR | 253.8% |
| 2014 FY | 167.07 Million INR | 248.54% |
| 2013 Q3 | 8.79 Million INR | -70.62% |
| 2013 FY | -112.47 Million INR | -1893.69% |
| 2013 Q1 | 28.86 Million INR | 153.06% |
| 2013 Q2 | 29.92 Million INR | 3.66% |
| 2012 Q2 | 62.19 Million INR | 8.97% |
| 2012 Q4 | -54.4 Million INR | 16.07% |
| 2012 Q3 | -64.82 Million INR | -204.23% |
| 2012 FY | 6.27 Million INR | 0.0% |
| 2012 Q1 | 57.07 Million INR | 0.0% |
| 2011 FY | - INR | -100.0% |
| 2011 Q3 | -27.49 Million INR | 0.0% |
| 2010 FY | 227.08 Million INR | 37.65% |
| 2009 FY | 164.97 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Biocon Limited | 50.83 Billion INR | 99.943% |
| Blue Jet Healthcare Limited | 3.37 Billion INR | 99.136% |
| Concord Biotech Limited | 6.26 Billion INR | 99.535% |
| Dishman Carbogen Amcis Limited | -413 Million INR | 107.053% |
| Jubilant Ingrevia Limited | 2.93 Billion INR | 99.009% |
| Panacea Biotec Limited | - INR | -Infinity% |
| Piramal Pharma Limited | 4.31 Billion INR | 99.325% |
| SMS Lifesciences India Limited | 359.47 Million INR | 91.896% |
| Supriya Lifescience Limited | 1.57 Billion INR | 98.147% |
| Syngene International Limited | 6.46 Billion INR | 99.55% |
| TAKE Solutions Limited | -213.49 Million INR | 113.645% |
| Zota Health Care Limited | -129.79 Million INR | 122.443% |